Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03260504 · ClinicalTrials.gov registry record · Phase 1
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03260504 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 6 participants.
The verdict
NCT03260504, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body. Aldesleukin may stimulate white blood cells to kill kidney cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to avoid recognition by immune cells. Giving aldesleukin and pembrolizumab may work better in treating patients with kidney cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-08-28 |
| Est. Completion | 2022-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03260504
The ClinicalTrials.gov registry entry for NCT03260504 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03260504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03260504 about?
NCT03260504 is a clinical study titled "Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer". This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body. Aldesleukin may stimulate white blood cells to kill kidney cancer cells. Immunotherapy with monoclonal a...
What is the current status of trial NCT03260504?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-08-28. Estimated completion is 2022-07-26.
What interventions are being tested in trial NCT03260504?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03260504?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.